Effect of Mupirocin in patients with refractory chronic rhinosinusitis - A prospective, randomised double-blinded controlled trial

Phase 2

Recruiting

• Conditions: Chronic Rhinosinusitis; Infection - Studies of infection and infectious agents

• Registration Number: ACTRN12611000994987
• Lead Sponsor: The Queen Elizabeth Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-09-19
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Patients with surgically-recalcitrant, S.aureus-positive chronic rhinosinusitis

Exclusion Criteria

Mupirocin allergy.
Augmentin Duo allergy.
Multiple bacterial species on culture.
MRSA.
Mupirocin-resistant S.aureus.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
S.aureus infection, as assessed by endoscopically-guided nasal swab[At end of 4-week treatment]

Secondary Outcome Measures

Name	Time	Method
Signs and symptoms of chronic rhinosinusitis, as assessed by the sinonasal outcome test (SNOT-20) and the Lund-Kennedy endoscopic examination score.[At end of 4-week treatment]